Distinct mono‐ and bivalent SM, such as Birinapant (TL32711; Condon et al, 2014) and BV6 (Varfolomeev et al, 2007), have been shown to induce cell death in B‐ALL primary patient samples and patient‐derived xenograft (PDX) cells in a RIPK1, TNFR1‐ and/or TNFR2‐dependent manner (Fakler et al, 2009; Belz et al, 2014; McComb et al, 2016; Richmond et al, 2016; Schirmer et al, 2016; Aguadé‐Gorgorió et al, 2020; Zinngrebe et al, 2020). This evidence concerns the gene RIPK1 and acute lymphoblastic leukemia.